{"id":6484,"date":"2026-03-23T22:09:51","date_gmt":"2026-03-23T16:39:51","guid":{"rendered":"https:\/\/www.businessupturn.com\/trade-policy\/?p=6484"},"modified":"2026-03-23T22:09:51","modified_gmt":"2026-03-23T16:39:51","slug":"pharma-giants-takeda-and-lilly-caught-fudging-drug-safety-tests-anti-diabetic-drug-pioglitazone-causes-bladder-cancer","status":"publish","type":"post","link":"https:\/\/www.businessupturn.com\/trade-policy\/pharma-giants-takeda-and-lilly-caught-fudging-drug-safety-tests-anti-diabetic-drug-pioglitazone-causes-bladder-cancer\/6484\/","title":{"rendered":"Pharma giants Takeda and Lilly caught fudging drug safety tests: Anti-Diabetic drug Pioglitazone causes bladder cancer"},"content":{"rendered":"

The U.S. Supreme Court\u2019s decision on March 23, 2026, to decline a challenge from Takeda Pharmaceutical Co<\/a>. and Eli Lilly & Co. has cleared the way for a high-stakes racketeering lawsuit. The ruling allows a massive class-action suit to proceed under the Racketeer Influenced and Corrupt Organizations (RICO) Act, a statute traditionally associated with organized crime, marking a pivotal moment in pharmaceutical litigation. The core of this litigation is not just the safety of the drug, but the alleged \u201centerprise\u201d of deception. By allowing the case to move forward under RICO, the court has signaled that if pharmaceutical companies are found to have systematically coordinated the suppression of safety data to inflate profits, they can be held liable for triple damages.<\/p>\n

The plaintiffs, primarily insurance companies and union health funds, allege that Takeda and Lilly engaged in a \u201cpattern of racketeering activity\u201d by misrepresenting the bladder cancer risks of Actos to physicians and the public. This allowed them to charge premium prices for a drug that, had its full risks been known, would have seen significantly lower demand or lower pricing.<\/p>\n

The drug in question is Actos (Pioglitazone), <\/b>an oral antidiabetic drug used to improve glycemic control in adults with type 2 diabetes. It belongs to the thiazolidinedione class, which works by increasing the body\u2019s sensitivity to insulin. The link to bladder cancer became a central controversy following long-term observational studies. Research suggested that Pioglitazone could lead to the formation of micro-crystals in the bladder or induce cellular changes in the bladder lining (urothelium), potentially triggering malignant growth. In 2011, the FDA<\/a> issued a safety communication noting that use of Actos for more than one year might be associated with an increased risk of bladder cancer. This led to several countries, including France and Germany, suspending the drug\u2019s use entirely. The current RICO lawsuit hinges on the claim that the companies were aware of these signals far earlier than they disclosed them, effectively \u201cgaming\u201d the regulatory and marketing landscape.<\/p>\n

The Indian Scenario: From ban to reintroduction<\/b><\/h3>\n

The history of Actos in India has been a regulatory rollercoaster, reflecting the global concern over its safety. In\u00a0 2013, following the global reports of bladder cancer, the Indian Ministry of Health and Family Welfare<\/a> briefly banned the manufacture, sale, and distribution of Pioglitazone in June 2013. However, the ban was lifted a few months later after intense lobbying by medical associations and pharmaceutical bodies, who argued that the drug was an affordable and effective option for India\u2019s massive diabetic population and that the cancer risk was statistically low for Indian patients.<\/p>\n

Currently, Pioglitazone (Actos) remains available in India, though it is heavily regulated. It is marketed by several Indian domestic pharmaceutical giants (such as Sun Pharma<\/a>, Lupin<\/a>, and Zydus<\/a>) under various brand names through licensing or generic manufacturing. However, the Drugs Controller General of India<\/a> (DCGI) mandates that the drug must carry a Box Warning<\/em> on its packaging, explicitly stating the potential risk of bladder cancer and advising that it should not be used as a first-line treatment.<\/p>\n

The case remains essential in the US Supreme Court as it represents a shift from Product Liability<\/em> (suing because a drug caused physical harm) to Economic Fraud<\/em> (suing because the drug was marketed under false pretenses). If the plaintiffs succeed under RICO, it could set a precedent where pharmaceutical companies are treated less like negligent manufacturers and more like organized entities engaged in financial deception. For the Indian market, where Pioglitazone remains a staple in diabetes management, the outcome of this U.S. litigation will likely prompt renewed scrutiny from health activists and the Central Drugs Standard Control Organisation<\/a> (CDSCO).<\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. Supreme Court\u2019s decision on March 23, 2026, to decline a challenge from Takeda Pharmaceutical Co. and Eli Lilly\u2026<\/p>\n","protected":false},"author":469,"featured_media":6489,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,53,2],"tags":[3759,3758,3755,612,3757,2855,3756,3141,3754,2854],"class_list":["post-6484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-india","category-policy","category-united-states","tag-central-drugs-standard-control-organisation","tag-drugs-controller-general-of-india","tag-eli-lilly-co","tag-fda","tag-indian-ministry-of-health-and-family-welfare","tag-lupin","tag-racketeer-influenced-and-corrupt-organizations-rico-act","tag-sun-pharma","tag-takeda-pharmaceutical-co","tag-zydus"],"reading_time":"4 min read","_links":{"self":[{"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/posts\/6484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/users\/469"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/comments?post=6484"}],"version-history":[{"count":3,"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/posts\/6484\/revisions"}],"predecessor-version":[{"id":6510,"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/posts\/6484\/revisions\/6510"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/media\/6489"}],"wp:attachment":[{"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/media?parent=6484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/categories?post=6484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessupturn.com\/trade-policy\/wp-json\/wp\/v2\/tags?post=6484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}